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Abstract 
Background: Recurrent convulsions can cause irreversible astrocyte death, impede neuron regeneration, and further 
aggravate brain damage. MicroRNAs have been revealed as players in the progression of numerous diseases including 
cancer and Alzheimer’s disease. Particularly, microRNA has been found linked to seizure-induced neuronal death. In 
this study, a rat model of recurrent convulsions induced by flurothyl treatments was utilised to assess the alterations 
of microRNA expressions in hippocampus tissues. We also applied an in vitro model in which primary astrocytes were 
exposed to kainic acid to verify the targets of miR-34b-5p identified in the animal model.
Results: We discovered that miR-34b-5p, a member of the miR-34 family, increased significantly in flurothyl-treated 
rat hippocampus tissue. More surprisingly, this upregulation occurred concurrently with accumulating astrocyte 
apoptosis, indicating the involvement of miR-34b-5p in seizures caused astrocyte apoptosis. Results from the in vitro 
experiments further demonstrated that miR-34b-5p directly targeted Bcl-2 mRNA, translationally repressed Bcl-2 pro-
tein, and thus modulated cell apoptosis by influencing Bcl-2, Bax, and Caspase-3.
Conclusion: Our findings prove microRNAs play a role in mediating recurrent convulsions-induced astrocyte death 
and further indicate that miR-34b-5p could acts as a regulator for astrocyte apoptosis induced by recurrent seizures.
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Background
Status epilepticus (SE), a prolonged seizure, has a higher 
prevalence in children than adults. Nearly 40  % of SE 
occurs in infants less than 2  years [1]. Recurrent con-
vulsions associated with SE during neonatal develop-
ment cause irreversible brain damage. Children develop 
impairments in physical activity, cognition, and language 
abilities, devastating both patients and caregivers [2–6]. 
Exploring the mechanisms and treatments of recurrent 
convulsions has become an emerging primary focus in 
clinical research.
Astrocytes play a critical role in enabling the central 
nervous system (CNS) to maintain its normal structure 
and function [6–8]. Disrupted astrocyte function is 
linked to various CNS diseases and the relation of astro-
cytes with SE has been unveiling. There is emerging evi-
dence showing that astrocytes involve in the pathological 
remodeling process of SE. Their dysfunctions have been 
linked to the failure of brain homeostasis in epilep-
tic patients who suffered from hippocampal sclerosis 
as well as kainic acid-induced mouse SE model [9–11]. 
MicroRNA, an evolutionally conservative class of small 
non-coding RNA, extensively affects the progression of 
diseases including neurodegenerative disease, traumatic 
brain injury, and brain cancer [12]. Specifically, a series 
of data demonstrate that microRNAs can regulate neural 
cell specification. Several microRNA families have also 
been shown to be involved in regulating the proliferation 
and survival of astrocytes, suggesting that microRNAs 
play essential roles in astrocyte functions [13–15].
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The miR-34 family is composed of three mature non-
coding microRNAs-miR-34a, miR-34b, and miR-34c-
found at three different loci across the genome. Among 
these, miR-34a has been studied extensively and consid-
ered a promising target for cancer therapies [16]. Previ-
ous studies have revealed that miR-34a interplays with 
key cell proliferation and death molecules in cancer cells, 
including p53, the Bcl-2 family, c-Myc, and PDGF. Spe-
cifically, p53-activated miR-34a inhibits cell growth by 
downregulating the expression of E2F, c-Myc, CDK4, 
CDK6, CyclinD1, and CyclinD2 [17–19]. Overexpression 
of miR-34a in several cancer cell lines induces pro-cas-
pase-3 activation and PARP disassociation, resulting in 
caspase-3-dependent cell death [20]. Moreover, miR-34a 
mRNA level is negatively correlated with Bcl-2 protein 
level and directly modulates Bcl-2 expression in hepa-
tocellular carcinoma (HCC) [21]. In the CNS, Agostini 
et al. [22] show that miR-34a can mediate SYT-1 and Syn-
taxin-1A expression, inhibit their functions, and reshape 
hippocampal spinal morphology, suggesting potential 
roles for miR-34s in CNS diseases. Sano et  al. [23] also 
demonstrated the upregulation of micro-34a during 
seizure-induced neuronal death, further indicating the 
involvement of miR-34 family in seizure pathology.
Currently, the majority of research in this field empha-
sises the study of miR-34a. But the function and regula-
tion of miR-34b and miR-34c remain poorly understood, 
especially regarding their roles in the CNS. In this paper, 
we discovered that one subtype of miR-34b—miR-
34b-5p—mediated astrocyte apoptosis caused by recur-
rent flurothyl-induced seizures in the way in which they 
directly targeted Bcl-2.
Methods
Animals and animal experimental designs
The rat model of recurrent convulsions was established 
by exposing rats to flurothyl. A total of 96 20-day-
old Sprague–Dawley rats were randomly divided 
into control and flurothyl-treated groups. To expose 
a rat to flurothyl, the rat was relocated to a chamber 
(40  cm ×  20  cm ×  20  cm), and the relocation was fol-
lowed by an infusion of 0.1  ml flurothyl (bis(2,2,2-
trifluoroethyl), Sigma-Aldrich, USA) to a gauze pad 
suspended inside the chamber. Once the flurothyl infu-
sion step was complete, the chamber was sealed by the 
experimenters. Because flurothyl is a highly volatile 
chemoconvulsant, the rats assigned to the flurothyl-
treated group were exposed to the chemical immediately. 
Thirty minutes after the first generalised seizure appeared 
in a rat, the rat was removed from the chamber to a 
normal environment. This flurothyl-seizure induction 
protocol was performed once a day for six consecutive 
days. The rats in the control group underwent the same 
operations including the relocation to the chamber and 
exposure to solutions. But the rats in the control group 
did not be exposed to flurothyl. To collect samples at sev-
eral different time points according to our experimental 
design, we anaesthetised rats with ketamine (40  mg/kg) 
and lidocaine (0.4 % 10 mg/kg), then performed cardio-
perfusion with 40 ml PBS followed by brain tissue extrac-
tion. Time points included in this experiment were: 24 h 
before flurothyl treatment, 2 h after flurothyl treatment, 
6  h after flurothyl treatment, 1  day after flurothyl treat-
ment, 3  days after flurothyl treatment and 7  days after 
flurothyl treatment. Each time point further included 
control group and seizured group (n  =  8/group/time 
point). All animals used in this project were provided by 
the College of Animal Technology, Hunan Agricultural 
University. Rats were kept on a 12-h light–dark cycle 
with lights turned on at 6:00 a.m. and were given unlim-
ited access to food and water.
MicroRNA isolation, RNA isolation, reverse transcription, 
and quantitative real time PCR
Using an Ambion® mirVana™ MicroRNA Isolation Kit 
(TaqMan), we extracted total microRNAs from the rat 
hippocampus tissues at different time points after the 
6-day flurothyl treatments were completed. Total RNAs 
from hippocampus tissues and cultured astrocytes 
were isolated using TRIzol (Invitrogen, USA). Reverse 
transcription of microRNAs was performed using the 
TaqMan MicroRNA Reverse Transcription system. 
Quantitative real time PCR (qPCR) was carried out with 
TaqMan Universal PCR Master Mix and TaqMan rodent 
microRNA fluidic cards. The amplification process was 
done with a 7900 HT fast real time PCR system (Applied 
Biosystems). Data were analysed by SDS2.4 (ABI). 
Reverse transcription of mRNA was performed using 
a Fermentas reverse transcriptase system. Quantitative 
real time PCR for the rat miR-34b-5p (RiboBio, 5201) 
and U6 snRNA (RiboBio, 0201) was measured using a 
Thermo Scientific Maxima SYBR Green/ROX qPCR 
Master Mix (2×) (Cat. K0221) following the procedures 
laid out by the manufacturer. The primers used in qRT-
PCR are listed as follows: Bcl-2 F: 5′-GGCATCTTCT 




The reverse transcription step started by mixing the fol-
lowing reagents: 0.8  μl Megaplex™ RT Primers (10×), 
0.2 μl dNTPs with dTTP (100 mM), 1.5 μl MultiScribe™ 
Reverse Transcriptase (50  U/μl), 0.8  μl 10×  RT Buffer, 
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0.9 μl MgCl2 (25 mM), 0.1 μl RNase Inhibitor (20 U/μl), 
0.2 μl Nuclease-free water, and 3 μl total extracted RNA. 
The mixture was then kept on ice for 5  min before put 
in Real-Time PCR System(7900HT) (Applied Biosystem, 
USA) for reaction. The amplification steps are described 
here: 40 cycles of 16 °C 2 min, 42 °C 1 min and 50 °C 1 s, 
followed by 5 min 85 °C and 4 °C forever. The PCR prod-
ucts was store in −20 °C for use.
To perform microarray experiments, we used 900  μl 
PCR mix for each miRNA TLDA (Taqman Low density 
array, Applied Biosystem). The PCR mix was composed 
of 450 μl TaqMan® Universal PCR Master Mix, 6 μl RT 
product, and 444 μl Nuclease-free water. Later, this PCR 
mix was added to TaqMan Rodent MicroRNA A  +  B 
cards and placed in 7900HT real-time PCR machine for 
the reaction. The reaction condition was: 95  °C 10 min; 
40 cycles of 15 s 95 °C, 60 s 60 °C. Each sample had quad-
ruplicate. U6 was used as loading control.
The results were analysed using SDS2.4 software (ABI).
Cell culture
McCarthy methods for primary rat hippocampal astro-
cyte culture have been described previously [24]. 2-day 
Newborn Sprague–Dawley rats were euthanised with 
CO2 and sterilised thoroughly by immersion in 75  % 
ethanol for 5 min. Under sterile conditions, the rat brains 
were collected and washed twice with cold D-Hanks 
solution. Under a microscope, we carefully detached the 
meninges and adjoining blood vessels from brain tissues 
and then separated the hippocampus from the whole 
brain. We then cut the hippocampus into small pieces 
and transferred the chopped hippocampus tissue to a 
15 ml conical tube containing 1 ml 0.25 % trypsin (Sigma, 
St Louis, MO, USA) for digestion. The digestion step was 
completed below 37 °C for 20 min and stopped by adding 
a culture medium containing fetal bovine serum. Follow-
ing the digestion step, we filtered the digested solution 
through 200-mesh CellCribble, collected filtrate, and 
centrifuged the filtrate for 10 min at 1000 rpm. We then 
discarded the supernatant, resuspended the cells with 
the astrocyte culture medium, and moved the suspended 
solution to a 25 cm2 flask. Then, we enriched the astro-
cyte concentration by a differential adhesion method 
in which a 60-min centrifugation was used to sepa-
rate astrocytes from attached mesenchymal cells. The 
astrocyte culture medium, we used was DMEM based, 
supplemented with 20  % fetal bovine serum (Hyclone, 
USA), 2  mmol/l l-glutamine, and penicillin–strepto-
mycin (100 μmol/ml). For this experiment, 1 × 106/well 
enriched astrocyte cells were seeded on a 25  cm2 flask 
coated with poly-l-lysine and supplied with 5 % CO2 at 
37 °C.
Western blot
Protein samples from the hippocampus tissues and pri-
mary astrocytes were loaded to a 12 % SDS-PAGE. PVDF 
membranes were used for the SDS-PAGE. The mem-
brane was blotted for 2 h using 5 % non-fat milk in the 
TBST solution. Antibodies against Bcl-2 (1:200), Cas-
pase-3 (1:1000), and Actin (1:1000) were purchased from 
Santa Cruz Biotechnology. HRP conjugated secondary 
antibodies against mice IgG and rabbit IgG (1:5000) were 
purchased from Proteintech Group, USA. Quantitative 
data of western blots were analysed using Gel-Pro4.0 
software. The intensity of the tested protein bands was 
normalised to the internal reference.
TUNEL
In situ terminal deoxynucleotidyltransferase mediated 
dUTP nick end labeling of fragmented DNA (TUNEL) 
was used to analyse the apoptosis of hippocampal neu-
rons and primary cultured astrocytes. Rat brain tissues 
were collected 1 day after the 6-day treatment was com-
pleted and then embedded with paraffin. Hippocampal 
neuron apoptosis was observed by staining brain tissues 
with an in  situ cell death TUNEL kit (MK1020, Boster, 
China). Primary rat hippocampal astrocytes were seeded 
in a six-well plate at a density of 1  ×  105/well. After 
reaching 90  % of confluence, astrocytes were treated 
with 50 μM, 100 μM, 150 μM, or 200 μM kainic acid for 
24  h, followed by TUNEL staining (Roche, USA). Fluo-
rescent microscopy was then used to observe the results 
(Nikon, USA). We randomly chose five views under the 
microscope for each treatment group and calculated 
the number of TUNEL positive cells and total cells. The 
apoptotic rate was calculated by dividing the number of 
TUNEL positive astrocytes by the total number of cells. 
All images were analysed with NIS-Elements BR 3.0 pro-
vided by Nikon.
Transfections of plasmids and MicroRNA mimics 
and inhibitors
Transfections of plasmids and microRNA mimics and 
inhibitors were conducted using Lipofectamine2000 
(Invitrogen), following the procedures laid out by the 
manufacturer. Cells were plated in six-well plates. MiR-
34b-5p mimics (100  nM, Ribobio, Guangzhou, China); 
miR-34b-5p inhibitors (100  nM, Ribobio, Guangzhou, 
China); Bcl-2 siRNA (50 nM) (Qiagen, Hilden, Germany); 
and controls including miR-34b-5p m NC, miR-34b-5p 
i NC, and control siRNA were transfected into primary 
astrocytes when they reached 60–70  % confluence. 
In a luciferase assay, WT-pGL3-Bcl-2-3′ UTR, MUT-
pGL3-Bcl-2-3′ UTR, or pGL3-control plasmid (200  ng, 
Ribobio, Guangzhou, China) was co-transfected with 
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control plasmid phRL-nμll (80  ng) into hippocampal 
astrocytes cultured in 24-well plates. MiR-34b-5p mim-
ics and inhibitors as well as miR-34b-5p i NC and miR-
34b-5p m NC were designed by Ribobio, Guangzhou, 
China. Available sequences are as follows: Bcl-2 siRNA 
sense 5′-UGGAUGAUCGAGUACCUGAdT dT-3′; anti- 
sense5 ′-UCAGGUAC UCAGUCAUCCAdCdA-3 ′ ; 




Cells at density of 1  ×  105/well were plated in 24-well 
plates  24  h before transfection. Luciferase constructs 
containing firefly luciferase with either WT Bcl-2 3′-UTR 
or mutant Bcl-2 3′-UTR were co-transfected into the 
cells with luciferase construct containing Renilla lucif-
erase driven by thymidine kinase promoter (an internal 
control). Cell lysates were collected 48 h after the trans-
fection, and the luciferase activity measurement was 
done following the procedures laid out by the manufac-
turer (Dual-Luciferase system, Promega, E1910). WT 
Bcl-2 plasmid was cloned using F:5′-GAATCTAGAGGT
CGACAAACCTGCCCCAAAC-3′ R:5′-AATGGCCGG 
CCTGGCAGTAAATAGCTGATTCGAC-3′. Mutant Bcl-2 
was cloned using the following primers: (underlining 
indicates mutation sites) F:5′-GAATCTAGAGGTCGA
CAAACCTGCCCCAAAC-3′ R: 5′-AATGGCCGGCCT 
CCCACTAA ATAGCTGATTCGACC-3′.
Statistical analysis
For the purpose of miRNA profiling, a twofold change 
with P  <  0.05 was considered significant. Data in this 
study are presented as mean SEM and were analysed 
by SPSS 18.0. Data was analysed with Student’s t test or 
one-way ANOVA followed by an LSD-t test. P < 0.05 was 
considered statistically significant. N of each statistical 
analyses is included in figure legends.
Results
Induced apoptosis in rat hippocampus after recurrent 
seizures
Neural cell apoptosis in the hippocampus had been 
observed in tissue samples from epileptic patients since 
the early nineteenth century. Staining and western blot-
ting of samples from human patients with temporal lobe 
epilepsy showed evidence of altered apoptotic signaling 
[25, 26]. Specifically, in both rodent models and human 
biopsy samples, astrocyte apoptosis was observed and 
considered to serve as a primary event happening dur-
ing post-convulsion pathological development [27]. In 
order to study the role of microRNAs in mediating brain 
damage related to recurrent convulsions, we used a rat 
model of recurrent convulsions in which we exposed rats 
to flurothyl for six consecutive days. All the rats assigned 
to the flurothyl treatment group displayed a phenotype of 
recurrent convulsions, while those in the control group 
remained normal. We also analysed cell death in hip-
pocampus tissue using TUNEL staining. In conformity 
with previous studies, we observed a higher percentage 
of TUNEL-positive cells in the hippocampus tissues from 
rats in the flurothyl-treated group than we did in tissues 
from the control group (Fig. 1a).
Bcl-2 protein has been thought of as an anti-apoptotic 
protein, while protein Bax, in the same family, has been 
considered a pro-apoptotic protein. The ratio of Bax to 
Bcl-2 levels was used as a determining checkpoint for 
cell apoptosis [28]. Autopsy studies in epileptic patients 
showed altered protein levels of Bcl-2 and Bcl-xl families 
in relation to neuron apoptosis, indicating that apop-
totic events occurred in post-seizure periods [29]. To 
determine how the Bax/Bcl-2 ratio was altered in our rat 
model of recurrent seizures in relation to cell apoptosis, 
we collected hippocampal tissue samples from rats in 
the flurothyl-treated group and the control group at five 
time points: 2  h, 6  h, 1  day, 3  days, and 7  days after all 
the flurothyl treatments had been completed. We then 
evaluated the Bax, Bcl-2, and caspase-3 protein levels of 
all collected samples. For all time points we examined, 
the Bcl-2 protein level slowly decreased over time, along 
with a gradual increase of Bax protein. The protein level 
of Bcl-2 did not show a significant difference between the 
control and flurothyl-treated group at 2 h after the 6-day 
treatment was completed (t14 =  0.81, P =  0.432). How-
ever, starting at 6 h after the treatments were finished, a 
difference in Bcl-2 protein levels began to appear between 
the control group and the flurothyl-treated group. By 
day 1, day 3, and day 7 after treatment completion, the 
Bcl-2 protein level of rat hippocampus in the flurothyl-
treated group was statistically significantly lower than 
the level in the control group (day 1:t14  =  15.46; day 
3: t14  =  17.83; day 7: t14  =  28.29; for all time points: 
P < 0.0001). Conversely, starting at 2 h after treatments 
were finished, the Bax protein level of rat hippocampus 
in the flurothyl-treated group gradually increased while 
remaining stable in the control group (Fig. 1b). And, Bax 
protein levels do present significantly increase starting 
from 2 h from treatment ended to 7 days after flurothyl 
treatment ended (2  h:t14  =  13.10; 6  h: t14  =  10.01; day 
1:t14 = 19.24; day 3:t14 = 9.04; day 7: t14 = 7.4; for all time 
points: P  <  0.0001). Overall, the Bax/Bcl-2 ratios of rat 
hippocampus in the flurothyl-treated group at all time 
points were statistically significant higher than the ratios 
for the control group (2 h: t14 = 8.53; 6 h: t14 = 8.33; day 
1:t14 = 12.83; day 3:t14 = 10.94; day 7: t14 = 14.72; for all 
time points: P  <  0.0001). Moreover, the Bax/Bcl-2 ratio 

















Fig. 1 Cell apoptosis and miR-34b-5p expression induced in rat hippocampus after flurothyl treatments. a Pictures of TUNEL staining (400) showed 
seizured mice with more cell death in both the CA1 and DG regions. DAB detection; representative of eight mice; scale bars, 100 μm. b Western 
blotting. Hippocampal tissue protein was extracted from control and flurothyl-treated rats at 2 h, 6 h, 1 day, 3 days, or 7 days after treatments were 
completed. Bcl-2, Bax, pro-caspase-3, and caspase-3 were blotted for analyses. c Bax/Bcl-2 ratio (n = 8, comparing seizured rat tissue with control 
rat tissue at different time points, 2 h: t14 = 8.53; 6 h: t14 = 8.33; day 1: t14 = 12.83; day 3: t14 = 10.94; day 7: t14 = 14.72; ***P < 0.0001). d Heat map 
summarising the patterns of expression for 72 microRNAs that were differentially expressed in hippocampal tissue of either the control or the 
flurothyl-treated group at one day after treatments were completed (n = 3). e Relative level of miR-34b-5p. n = 8 animals in each group (one-way 
ANOVA, n = 8, F5,42 = 157.5; **1 day versus 6 h or 2 h, P < 0.01; ***1 day, 6 h or 2 h versus control P < 0.0001)
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continued to increase through all time points during 
the post-seizure period, while remaining low and stable 
in the control group (Fig. 1c). Similarly, the cleaved cas-
pased-3 level of rat hippocampus in the flurothyl-treated 
group stayed significantly higher than the level in the 
control group for all post-seizure time points we exam-
ined (P < 0.0001 for all time points). The highest level of 
cleaved caspase-3 appeared at 1  day after the flurothyl 
treatments were completed, indicating that the preva-
lence of apoptotic cells peaked at this time point (Fig. 1b). 
These data demonstrated that cell death occurred in the 
hippocampus tissues of flurothyl treated rats as a result 
of seizure.
MicroRNA transcriptome in rats treated with flurothyl 
and the induction of miR‑34b‑5p
Given the existence of neuron apoptosis in several 
CNS diseases and the accumulated evidence showing 
that microRNAs mediate cell apoptosis in the CNS, we 
decided to explore microRNA transcriptome using an 
array-based microRNA profiling technique [30, 31].
We characterised and compared the microRNA pro-
files of the hippocampus tissues from experimental and 
control groups (Fig.  1d). In total, we selected microR-
NAs changes more than twofold with p value smaller 
than 0.05 and listed the top 30 altered microRNAs 
whose expressions were either upregulated or down-
regulated the most. Among these altered microRNAs, 
nine microRNAs were upregulated and 21 microRNAs 
were downregulated (Table 1). Among these candidates, 
miR-34b-5p attracted our attention because of previous 
studies about the miR-34 family in CNS diseases. Com-
pared to miR-34b-5p, several other microRNAs, such as 
miR-1306, changed more dramatically. However, these 
microRNAs had either already been studied in detail by 
other groups or else shown insufficient evidence to date 
of association with diseases. MiR-34b, miR-34c, which 
locate in the same transcriptional unit as miR-34b, were 
moderately upregulated. Our array data showed that 
the miR-34b-5p level was upregulated seven fold in the 
hippocampus tissues of rats treated with flurothyl. To 
re-confirm this upregulation of miR-34b-5p discovered 
in the array data, we performed quantitative stem-loop 
polymerase chain reaction (qRT–PCR) in the hippocam-
pus tissue samples collected at different time points and 
successfully validated the significant upregulation of 
miR-34b-5p in hippocampus tissues from rats treated 
with flurothyl (Fig. 1e, P < 0.0001). By 2 h after the 6-day 
flurothyl treatment, a fivefold increase of miR-34b-5p 
was observed. By day 1 when most pro-caspase-3 was 
cleaved into active caspase-3, a peak sevenfold induction 
in miR-34b-5p level was observed. By day 3 and day 7, the 
expression level of miR-34b-5p gradually decreased to 
normal. One observation, that the trend of miR-34b-5p 
level was similar to the trend of cleaved caspase-3 across 
all post-seizure time points we studied, indicated that 
the initiation of cell apoptosis events could be correlated 
with the changes of miR-34b-5p level (Fig. 1a, e).
MiR‑34b‑5p mediates kainic acid‑induced astrocyte 
apoptosis
To distinguish which hippocampus cell populations were 
undergoing apoptosis, we carefully analysed hippocam-
pal TUNEL staining results and found that a certain 
percentage of TUNEL positive cells was residing in the 
hilus and subgrandule zone of the hippocampal dentate 
gyrus, where abundant astrocytes are supposed to reside 
[32]. Given the fact that the upregulation of miR-34b-5p 
was observed and the previous study showing an asso-
ciation between astrocyte apoptosis and convulsions, we 
hypothesised that miR-34b-5p functionally contributed 
to astrocyte apoptosis in recurrent convulsions [27].
In the 1970s, kainic acid (KA) was found to induce hip-
pocampal neuronal apoptosis, and it has been widely 
used as an experimental drug for convulsion models since 
then [33, 34]. Specifically, KA has been shown to activate 
glutamate receptors, induce ROS, affect mitochondria 
function, and cause cell death in astrocytes [35]. Here, 
we tested whether miR-34b-5p mediated KA induced 
astrocyte apoptosis in vitro. We exposed primary astro-
cytes to different concentrations of KA and found that 









miR-1306 21.7655 Up miR-500 6.8923 Down
miR-448 21.0113 Up miR-215 6.0471 Down
miR-224 16.6746 Up miR-299 4.6631 Down
miR-204# 9.98247 Up miR-197 4.3048 Down
miR-
34b-5p
7.04904 Up miR-17# 4.1252 Down
miR-34c# 5.93634 Up miR-1 4.0987 Down
miR-28# 5.13192 Up miR-505 4.0758 Down
miR-204 4.92734 Up miR-350 3.4316 Down
miR-592 2.32224 Up miR-28 3.3122 Down
miR-183 257.0694 Down miR-98 3.2761 Down





24.2659 Down miR-29b 3.2111 Down
miR-721 11.3161 Down miR-203 3.1991 Down
miR-672 7.5489 Down miR-1188 3.0174 Down
miR-
493-3p
7.4394 Down miR-206 2.6099 Down
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the apoptotic rate increased significantly as the con-
centration of KA rose (P  <  0.0001, Fig.  2a and Addi-
tional file 1: Fig. 1). A 100 μM KA treatment sufficiently 
induced about 10  % cell apoptosis detected by TUNEL 
staining (Fig. 2a, b). Also, astrocytes treated with 100 μM 
KA expressed a high level of cleaved caspase-3, Bax and 
Bax/Bcl-2 ratio but low levels of Bcl-2 and pro-caspase-3 
(Fig. 2c–e). More importantly, in accord with our results 
from the in vivo rat model, we detected increased miR-
34b-5p expression in KA treated astrocytes (t8 =  9.775, 
P  <  0.0001; Fig.  2f ). To further confirm the correlation 
between miR-34b-5p level and KA-induced astrocyte 
apoptosis, we manipulated miR-34b-5p levels by treat-
ing primary astrocytes either with miR-34b-5p mimics or 
with miR-34b-5p inhibitors, followed by KA treatment. 
MiR-34b-5p mimics efficiently increased miR-34b-5p 
levels six-fold (difference among groups: F4,20  =  866.9, 
P  <  0.0001; Fig.  3b). Nearly 17  % of the total astrocytes 
underwent apoptosis in the group treated with mimics, 
while only about 10 % of the total astrocytes in the con-
trol group underwent apoptosis (Fig. 3a, c). In contrast, 
pre-treating primary hippocampal astrocytes to miR-
34b-5p inhibitors before KA treatment caused significant 
reduction in miR-34b-5p levels, and the percentage of 
apoptotic cells was greatly lowered, to less than 5 % (dif-
ference among groups: F4,20 = 67.45, P < 0.0001, Fig. 3a, 
c). These two results strongly support our hypothesis that 
miR-34b-5p mediates astrocyte apoptosis in response to 
KA treatment in vitro.
MiR‑34b‑5p mediates cell apoptosis by targeting Bcl‑2
Based on the results above, we further asked the question 
of how miR-34b-5p mediated astrocyte apoptosis. Using 
starBase (http://starbase.sysu.edu.cn/), we screened 
potential targets for miR-34b-5p based on sequence tar-
geting analysis. Among the hits we identified, Bcl-2 was a 
potential target for miR-34b-5p (Fig. 3e). With the aim of 
validating whether Bcl-2 was targeted by miR-34b-5p, we 
transfected astrocytes with luciferase reporter constructs 
containing either wild type Bcl-2 3′-UTR or mutant Bcl-2 
3′UTR. Next, we treated those transfected astrocytes 
with either miR-34b-5p mimics or control mimics. The 
miR-34b-5p level was successfully increased upon mim-
ics transfection (Additional file 2: Fig. 2A). The luciferase 
activity of WT Bcl-2 3′-UTR was significantly lowered 
by treatment with miR-34b-5p mimics (main difference 
between mimics treatment and control treatment in 
WT Bcl-2 3′-UTR: t4 = 7.10, P = 0.0021). On the other 
hand, luciferase activity of mutant Bcl-2 3′-UTR was not 
affected by treatment with miR-34b-5p mimics (main dif-
ference between mimics treatment and control treatment 
in MUT Bcl-2 3′-UTR: t4 = 0.9156, P = 0.4117; Fig. 3d). 
These results indicated that Bcl-2 3′-UTR could be 
targeted by miR-34b-5p mimics which affected the stabil-
ity or the translation efficiency of Bcl-2 mRNA. Then, to 
validate whether miR-34b-5p mediates apoptotic signal-
ing by modulating Bcl-2, we evaluated the protein lev-
els of Bcl-2, Bax, pro-caspase-3, and cleaved caspase-3 
in primary astrocytes treated with miR-34b-5p mimics, 
miR-34b-5p inhibitors, and the respective control mimics 
or inhibitors. Astrocytes treated with vehicle and miR-
34b-5p mimic controls or inhibitor controls have the 
same levels of Bcl-2, Bax, pro-caspase-3, and cleaved cas-
pased-3. However, miR-34b-5p mimic treatment reduced 
the endogenous level of Bcl-2 but increased the Bax level 
(Fig. 4a). Conversely, miR-34b-5p inhibitors caused accu-
mulation of Bcl-2 and pro-caspase-3 in astrocytes but 
reduction of Bax and cleaved caspase-3 (Fig.  4b). These 
data suggested that miR-34b-5p affected Bcl-2 and Bax 
protein levels and presented a pro-apoptotic function by 
modulating Bax/Bcl2 ratio expression (difference among 
five treatment groups, F4,20 = 123.8, P < 0.0001; Fig. 4c).
Finally, to confirm that the pro-apoptotic function of 
miR-34b-5p depends on Bcl-2, we performed co-trans-
fection of Bcl-2 siRNA and miR-34b-5p inhibitors in 
primary astrocytes. Transfection of miR-34b-5p mimics 
and inhibitors affected miR-34b-5p level correspondently 
(Additional file 2: Fig. 2B, Fig. 3b). Reducing Bcl-2 alone 
using siRNA could induce cell apoptosis represented by 
upregulating cleaved caspase-3 levels. Conversely, miR-
34b-5p inhibitor treatment alone inhibited cell death 
by reducing pro-caspase cleavage. However, astrocytes 
with miR-34b-5p treatment in the context of Bcl-2 
siRNA silencing increased active caspase-3 level com-
pared with the group treated with miR-34b-5p inhibitors 
alone, proving that miR-34b-5p induced cell apoptosis 
was Bcl-2 dependent (Fig. 4d–f). Interestingly, the Bcl-2 
mRNA level remains stable in response to treatment with 
miR-34b-5p mimics or inhibitors, but the effects of miR-
34b-5p on suppressing Bcl-2 mRNA translation efficiency 
have been proved by luciferase activity experiments and 
western blots (Figs. 3d, f, 4a, b). Thus, we think that the 
Bcl-2 protein suppression caused by miR-34b-5p is not 
achieved through affecting mRNA stability of Bcl-2 but 
that it could be achieved through translational repres-
sion mechanisms. Taken together, these results show that 
miR-34b-5p functions as a pro-apoptotic factor in astro-
cytes by mediating Bcl-2 protein levels.
Discussion
Understanding neuronal apoptotic mechanisms is 
pivotal in developing novel therapies for neurodegen-
erative diseases and related CNS diseases. Neuronal 
apoptosis, closely linked with Alzheimer’s disease, Par-
kinson’s disease, and epilepsy, is triggered by osmolytic 
stress and DNA damage induced by accumulation of 
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Fig. 2 MiR-34b-5p upregulation in kainic acid induced astrocyte apoptosis. a Primary astrocytes were treated with 50 μM, 100 μM, 150 μM or 
200 μM kainic acid for 24 h followed by TUNEL staining and quantification for the percentage of TUNEL positive cells. n = 5 for each treatment 
group (one-way ANOVA test, F4,20 = 70.24, ***P < 0.0001; **50 μM KA versus control, 50 μM KA versus 100 μM and 100 μM versus 150 μM P < 0.01, 
*** individual KA treatment versus control P < 0.0001). b Representative images of three repeated TUNEL staining experiments after 24-h kainic acid 
treatment; TUNEL (green), DAPI (blue); scale bar 50 μm. c–e Western blot and quantification. Cell lysate of 24 h 100 μM KA treated primary astrocytes 
was analysed with SDS-PAGE. Bcl-2, Bax, Pro-caspase-3, and caspase-3 were blotted. The significance difference of Bax/Bcl-2 was observed (n = 5, 
t8 = 12.93, ***P < 0.0001). f Quantitative PCR result: miR-34b-5p upregulated after 100 μM kainic acid treatment (n = 5, t8 = 9.775, ***P < 0.0001)
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free radicals [6]. Specifically, neuronal death caused 
by seizure occurs partially from excessive Na+ and 
Ca2+ entry due to excitotoxic glutamatergic neu-
rotransmission gating. Although certain processes, 
including death receptor activation, TNF/caspase-8 
signaling, and Bax activation induced by release of 
intrinsic cytochrome complex, are identified as causes 
of neuronal cell death, detailed regulation steps and 
the molecular players involved still remain elusive 
to researchers [36]. In this paper, we utilised a fluro-
thyl-induced recurrent convulsions model, explored 
whether microRNAs control astrocyte death, and dis-
covered miR-34b-5p connected to astrocyte apoptosis 
by affecting Bcl-2 mRNA translation.
In the present study, we investigated hippocampal 
microRNA transcriptome in rats with recurrent convul-
sions and identified transcriptional alterations of multiple 
microRNAs. Besides the miR-34s family, some of our top 
hits, such as miR-204, miR-488, and miR-183, have been 
investigated and proposed to regulate apoptosis, inflam-
mation, and ER stress in various systems [37–39]. Here, 
we focused primarily on miR-34b-5p. We observed that 
induction of miR-34b-5p began at 2 h after the recurrent 
convulsions model was established, remaining high till 
1 day after the establishment of recurrent seizure model, 
then returning to normal after 3  days. This expression 
patent of miR-34b-5p delineates its involvement in mod-
ulating neuronal damage in the early stage of convulsion-
caused damage. Given that preventing neuronal death in 
early disease stages would greatly improve therapeutic 
outcomes, therapies targeting miR-34b-5p may be benefi-
cial [40].
Accumulated evidence now supports the essential role 
of microRNAs during the development of CNS diseases, 
especially convulsions and convulsion-related epilepsy. 
Array-based microRNA profiling in both an experimental 
convulsion model and human epilepsy detected expres-
sion changes as well as complex regulations for various 
microRNAs [41–43]. Though the majority of cell death 
we observed involved astrocytes, a small population of 
hippocampus neurons also underwent cell death in our 
model, signifying the potential role of miR-34b-5p in 
neuron death as well. Much as with our findings, a recent 
study by Sano et al. [23] found that upregulation of micro-
RNA-34a and neuronal death co-existed and correlated 
with each other in a mouse seizure model. In our study, 
we explored the mechanisms of association of miR-34b-5p 
level with cell death in recurrent-seizure hippocampus. 
We found that miR-34b-5p was upregulated in astrocytes 
treated with kainic acid and discovered that the pro-apop-
totic function of miR-34b-5p was Bcl-2 dependent. Inter-
estingly, our results revealed that miR-34b-5p regulated 
Bcl-2 protein without interfering with its mRNA stabil-
ity in a certain time window, indicating that miR-34b-5p 
represses translation of Bcl-2 mRNA before moving it 
towards RISC-dependent degradation. Indeed, several 
recent studies have demonstrated that a large number of 
microRNAs primarily initiate translational repression in 
their target before degrading their mRNA targets rather 
than cause mRNA degradation immediately [44–46].
(See figure on next page.) 
Fig. 4 miR-34b-5p regulation of astrocyte apoptosis through mediating Bcl-2 expression level. a, b Western blot analysis for Bcl-2, Bax, pro-cas-
pase-3, and cleaved caspase-3. Cell lysates were prepared from astrocytes treated with vehicle control, mimics negative control (m NC) or inhibitors 
negative control (i NC), miR-34b-5p mimics or inhibitors. c Bax/Bcl-2 protein ratio after quantitative analysis (one-way ANOVA, n = 5, F4,20 = 123.8, 
***P < 0.0001). d Western blot protein analysis for Bcl-2 and actin. Cell lysates were prepared from cultured astrocytes treated with control siRNA, 
scramble siRNA, and Bcl-2 siRNA. e Western blot analysis for pro-caspase-3, cleaved caspase-3, and actin. Cell lysates were prepared after astro-
cytes were treated with control siRNA, Bcl-2 siRNA, miR-34b-5p inhibitors and Bcl-2 siRNA together, and miR-34b-5p inhibitors alone. f Quantita-
tive analysis for results in E (one-way ANOVA, pro-caspase-3 group, n = 5, F3,16 = 211.6, ***P < 0.0001; Caspase-3-19KD group, n = 5, F3,16 = 98.36, 
***P < 0.0001; Caspase-3-17 KD group, F3,16 = 158.7, ***P < 0.0001; ***on top of bars, comparing with control within same group; ***on top of lines, 
comparing between the individual bars the line covers, **P < 0.01, ***P < 0.0001)
(See figure on previous page.)  
Fig. 3 miR-34b-5p promotes KA-induced astrocytes apoptosis by targeting Bcl-2. a Representative images of three repeated TUNEL staining experi-
ments on cultured astrocytes. The astrocytes are pre-treated with of miR-34b-5p mimics, inhibitors, mimics negative control (mNC), and inhibi-
tors negative control (i NC), followed by KA treatment; scale bar 50 μm. b Relative miR-34b-5p levels after different treatments; (one-way ANOVA, 
n = 5, F4,20 = 866.9, ***P < 0.0001). c Percentage of TUNEL positive astrocytes over total counted astrocytes represented as apoptotic rate. Cells 
were treated with the four indicated treatments before fixing and performing TUNEL staining experiments (one-way ANOVA, n = 5, F4,20 = 67.45, 
***P < 0.0001). d Luciferase assay. Astrocytes was transfected with WT Bcl-2 3′-UTR or Mutant Bcl2 3′-UTR followed by treating either with control or 
miR-34b-5p mimics. Luciferase activity is indicated by the ratio of firefly luciferase activity to Renilla luciferase activity (Between miR-34b-5p mimics 
treated with WT-UTR or MUT-UTR, n = 3, t4 = 7.10, **P = 0.0021). e Graphic picture shows miR-34b-5p sequence match with rat Bcl-2 mRNA 3′-UTR. 
f Quantitative PCR shows Bcl-2 mRNA level in response to different treatments (one-way ANOVA, n = 5, F4,20 = 0.4576, P = 0.7658)
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Conclusion
To summarise, the present study contributes to an 
emerging focus on the function of microRNAs in the 
brain. We discovered that miR-34b-5p is induced by 
recurrent seizures in a rodent model of recurrent con-
vulsions and illustrated how miR-34b-5p mediates Bcl-2 
dependent caspase-3 activation and cell apoptosis. Our 
findings demonstrate a crucial role for miR-34b-5p in 
seizure-induced brain damage and the possibility that 
miR-34b-5p could serve as a novel therapeutic target for 
treating various neurological diseases.
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